NCT04391920 (CTC REGISTRY) is a clinical trial of CytoSorb 300 mL device in COVID-19, sponsored by CytoSorbents, Inc.

Who is sponsoring NCT04391920?

NCT04391920 is sponsored by CytoSorbents, Inc.

What drugs are being tested in NCT04391920?

Interventions in NCT04391920: CytoSorb 300 mL device.

Is NCT04391920 still recruiting?

NCT04391920 is currently completed. Last updated 9 February 2024.

Last reviewed 2024-02-09 · How we verify

NCT04391920: CTC REGISTRY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Registry of CytoSorb Therapy in COVID-19 ICU Patients

Completed Last updated 9 February 2024

What this trial tests

trial testing CytoSorb 300 mL device in COVID-19 in 138 participants. Completed in 20 January 2022.

Timeline

28 August 2020

Primary endpoint
20 January 2022

20 January 2022

Quick facts

Lead sponsor	CytoSorbents, Inc
Status	Completed
Study type	OBSERVATIONAL
Enrollment	138
Start date	28 August 2020
Primary completion	20 January 2022
Estimated completion	20 January 2022
Sites	7 locations across United States

Drugs / interventions tested

CytoSorb 300 mL device

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

CytoSorbents, Inc

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.
Labò N, Ohnuki H, Tosato G. · · 2020 · cited 57× · PMID 32629875 · DOI 10.3390/cells9071583
Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019.
Gracia-Hernandez M, Sotomayor EM, Villagra A. · · 2020 · cited 41× · PMID 33324210 · DOI 10.3389/fphar.2020.577571
CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry.
Song T, Hayanga J, Durham L, Garrison L, et al · · 2021 · cited 24× · PMID 34988092 · DOI 10.3389/fmed.2021.773461
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.
Hayanga JWA, Song T, Durham L, Garrison L, et al · · 2023 · cited 23× · PMID 37337243 · DOI 10.1186/s13054-023-04517-3
A Review of Extracorporeal Blood Purification Techniques for the Treatment of Critically Ill Coronavirus Disease 2019 Patients.
Niazi NS, Nassar TI, Stewart IJ, Honore PM, et al · · 2022 · cited 18× · PMID 35417433 · DOI 10.1097/mat.0000000000001761
Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility.
Damianaki A, Stambolliu E, Alexakou Z, Petras D. · · 2023 · cited 6× · PMID 37098671 · DOI 10.23876/j.krcp.22.223
Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients.
Napoli M, Provenzano M, Hu L, Bini C, et al · · 2022 · cited 2× · PMID 36362514 · DOI 10.3390/jcm11216286
Sepsis-Related Cardiomyopathy: Advances in Diagnosis and Treatment.
Sun B, Wu F, Zhang T. · · 2025 · cited 1× · PMID 41209137 · DOI 10.31083/rcm37044

Verify or expand the search:

Other trials of CytoSorb 300 mL device

Trials testing the same drug.

NCT04596813 — Role of Cytosorb in Left Ventricular Assist Device Implantation · NA · recruiting
NCT04131959 — Ticagrelor CytoSorb Hemoadsorption · NA · terminated

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other CytoSorbents, Inc trials

Trials by the same sponsor.

NCT05093504 — Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D) · NA · terminated
NCT05077124 — Safe and Timely Antithrombotic Removal (STAR) Registry · recruiting
NCT04976530 — Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) · NA · completed
NCT04131959 — Ticagrelor CytoSorb Hemoadsorption · NA · terminated
NCT03384875 — CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04391920 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CytoSorbents, Inc
Last refreshed: 9 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04391920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing